Management identified that the historical strategy of acquiring on-market specialty products is no longer capital efficient due to intensified competition and rising acquisition prices. The company is pivoting its business development focus toward oncology therapeutics, targeting on-market or late-stage development assets that leverage their existing community oncology footprint. Performance in Q4 2025 was intentionally impacted by a strategic 'sell-in' of Robodon in Q3 to ensure patient supply during ...

Assertio (NasdaqCM:ASRT) Q4 2025 Earnings call March 16, 2026 04:30 PM ET Company ParticipantsAjay Patel - CFODaniel Santos - SVPMark Reisenauer - CEOPaul Schwichtenberg - President and COORaghuram Selvaraju - Managing DirectorScott Henry - Managing DirectorConference Call ParticipantsNazibur Rahman - VP and Equity Research AnalystThomas Flaten - Senior Research AnalystOperatorLadies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I woul ...

Assertio (NasdaqCM:ASRT) Q4 2025 Earnings call March 16, 2026 04:30 PM ET Speaker4Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Assertio Holdings Fourth Quarter and Full Year 2025 Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during th ...

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Share Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026 LAKE FOREST, Ill--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio†or the "Company†) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated product ...

Financial Data and Key Metrics Changes - Assertio reported total product sales of $49.5 million for Q3 2025, up from $28.7 million in the prior year, primarily driven by the Rosedown two-quarter pull forward [13] - Adjusted EBITDA for Q3 2025 was $20.9 million, significantly up from $4.4 million in the prior year, largely due to higher Rosedown sales [16] - GAAP net income for Q3 2025 was $11.4 million, compared to a loss of $3 million in the prior year [16] Business Line Data and Key Metrics Changes - Rosedown net product sales reached $38.6 million in Q3 2025, a substantial increase from $15 million in the same quarter last year, attributed to the pull forward of sales [7] - Synthesan net product sales grew to $2.8 million in Q3 2025, up from $2.6 million in the prior year, driven by higher volume [8][13] - Indocin sales decreased to $4.8 million in Q3 2025 from $5.7 million in the prior year, reflecting impacts from generic competition [14] Market Data and Key Metrics Changes - Rosedown achieved a 43% market share in the clinic Medicare Part B segment in Q3 2025, reflecting strong demand and strategic distribution efforts [10] - The company experienced a 42% year-to-date demand growth for Rosedown compared to the same period in 2024 [10] Company Strategy and Development Direction - The company aims to maintain price stability and predictability for Rosedown while pursuing further demand and market share growth [12] - Assertio is currently reviewing and refining its strategies moving forward under new leadership, focusing on growth assets [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's potential to generate significant value for patients and shareholders, highlighting a solid balance sheet and core growth assets [6] - The company anticipates a temporary decline in cash flow due to the Rosedown sales transition but expects improvement in Q2 2026 [16] Other Important Information - Assertio has executed a long-term supply agreement with its API manufacturer, ensuring stable supply and pricing for Rosedown [11] - The company is tightening its 2025 guidance, expecting full-year product sales between $110 million and $112 million and adjusted EBITDA between $14 million and $16 million [17] Q&A Session Summary Question: Linkage between labeler code and ASP for Rosedown - Management clarified that the labeler code change is not tied to ASP and emphasized a strategy of price stability and predictability [20] Question: Comments on Indocin market performance - Management noted good market share and volume for Indocin despite competition, with some price favorability observed [21] Question: Optimizing Rosedown's promotional and reimbursement strategy - Management is currently reviewing all strategies and will provide updates as refinements are made [24] Question: Expectations for Synthesan sales acceleration - Management indicated that Synthesan is competing in a generic market with a focus on raising awareness and promoting its unique delivery mechanism [30]

Core Insights - Assertio Holdings reported strong financial results for Q3 2025, with significant growth in net product sales, particularly for Rolvedon, which saw sales increase to $38.6 million from $15.0 million year-over-year [7][2] - The company has narrowed its FY2025 net product sales guidance to a range of $110 million to $112 million and adjusted EBITDA guidance to $14 million to $16 million [5][1] - Paul Schwichtenberg has been promoted to President and COO, indicating a strategic focus on operational efficiency and commercial execution [6][8] Financial Performance - Rolvedon net product sales reached $38.6 million in Q3 2025, a 157% increase from $15.0 million in Q3 2024 [7] - Sympazan net product sales grew to $2.8 million in Q3 2025, up from $2.6 million in the prior-year quarter [7] - Indocin net product sales decreased to $4.8 million in Q3 2025 from $5.7 million in Q3 2024 due to generic competition [7] - Gross margin was reported at 72%, down from 74% in the prior-year quarter, attributed to a higher proportion of Rolvedon sales [7] - Adjusted EBITDA for Q3 2025 was $20.9 million, significantly up from $4.4 million in Q3 2024 [7] Guidance and Outlook - The updated guidance for FY2025 reflects the impact of the Rolvedon pull-forward and improved visibility into expected performance for the remainder of the year [5][2] - The company expects uninterrupted patient supply of Rolvedon, with regular sales of the newly labeled product anticipated to begin in Q2 2026 [7] Leadership Changes - Paul Schwichtenberg's promotion to President and COO is aimed at enhancing commercial strategies and driving future growth [8][6] - Schwichtenberg has a history of leadership roles within the company, focusing on operational and commercial execution [8]

Core Insights - Assertio Holdings, Inc. reported total net product sales of $28.8 million for the second quarter of 2025, a decrease from $30.7 million in the same period last year [1][3] - The company narrowed its guidance for net product sales and adjusted EBITDA for the full year, reflecting first-half performance and operational efficiencies [9] Financial Performance - Net product sales for the first half of 2025 totaled $54.8 million, down from $62.6 million in the first half of 2024 [3] - The net loss for the second quarter was $16.4 million, compared to a net loss of $3.7 million in the prior year quarter [3][20] - Adjusted EBITDA for the second quarter was $5.6 million, an increase from $3.1 million in the prior year quarter [3][20] Product Performance - Rolvedon achieved net product sales of $16.1 million, up from $15.1 million in the prior year quarter, driven by higher volume and favorable adjustments [6] - Sympazan's net product sales increased to $3.2 million from $2.7 million, attributed to additional sales support [6] - Indocin's net product sales decreased to $3.0 million from $6.9 million due to generic competition [6] Cost Management - Selling, general and administrative (SG&A) expenses decreased to $17.0 million from $18.4 million, aided by a one-time benefit from employee retention tax credits [6] - The company is streamlining operations and consolidating products from acquired subsidiaries to optimize costs [2][14] Balance Sheet and Cash Flow - As of June 30, 2025, cash and investments totaled $98.2 million, up from $87.3 million at the end of the first quarter [5] - The company reported a debt of $40.0 million, consisting of 6.5% convertible notes with no maturities until September 2027 [7] Strategic Initiatives - Assertio has ceased commercialization of Otrexup to focus on core growth assets and improve operating expenses [14] - The company plans to present new data on Sympazan at the American Neurological Association Annual Meeting in September [14]

Financial Data and Key Metrics Changes - In Q1 2025, net product sales were $26 million, slightly ahead of expectations, compared to $31.9 million in the prior year quarter [6][15] - Gross margin increased to 70% from 65% a year ago, although the prior year's gross margin was 78% when excluding inventory step-up [17] - GAAP net income for Q1 was a loss of $13.5 million, compared to a loss of $4.5 million in the prior year [19] - Adjusted EBITDA for Q1 was $200,000, down from $7.4 million in the prior year quarter [19] Business Line Data and Key Metrics Changes - ROLVOIDON sales were stable, with strong demand expected to continue [6][7] - SYMPAZAN prescriptions increased by 6.5% year over year, indicating a positive trend [7] - Indocin sales were $5.5 million, down from $8.7 million in the prior year due to generic competition [16] Market Data and Key Metrics Changes - The company is focusing on expanding payer coverage, having recently strengthened relationships with Cigna [6][10] - The primary business for ROLVOIDON is in community oncology Medicare Part B, with plans to expand into hospital settings [31] Company Strategy and Development Direction - The company is in a transformation phase aimed at reducing legal exposure, simplifying corporate structure, and prioritizing growth investments [10][11] - The growth phase is expected to begin in 2026, with a focus on becoming a leading specialty pharma company [10][14] - The company plans to divest non-core assets to reallocate resources towards growth [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the full year net product sales and adjusted EBITDA outlook [6][21] - The company is optimistic about ongoing strategic conversations that may enhance its commercial portfolio [46] - Management does not foresee immediate risks from tariffs or drug pricing changes, given current inventory levels [59][61] Other Important Information - Cash and investments as of March 31, 2025, totaled $87.3 million, down from $100.1 million at the end of 2024 [19] - The company has settled multiple legal matters, which is expected to reduce legal costs moving forward [11][12] Q&A Session Summary Question: Was there any value movement regarding the opioid litigation matters? - Management indicated that there was nominal value received in the settlement [23] Question: How should cash be used to bring down accrued liabilities? - Management expects the use of cash to occur relatively evenly throughout the year [25] Question: Any updates on same day dosing and NCCN? - Management is executing a twelve-month strategy and hopes for publication in a peer-reviewed journal by mid-summer [27] Question: Progress on expanding Rovodon into hospital settings? - The strategy involves building payer coverage to unlock commercial channels and hospital access [32] Question: Why not adjust the adjusted EBITDA guidance down after Q1 results? - Management believes there are still too many variables to adjust the guidance down at this time [34] Question: Expectations for Indocin's generic competition? - Management anticipates two more generics entering the market in 2025, which will impact revenue [41] Question: Any updates on strategic business development? - Management is optimistic about ongoing positive conversations for potential growth opportunities [46] Question: Impact of tariffs and drug pricing changes? - Management does not foresee immediate risks from tariffs or drug pricing changes [59][61]

Financial Data and Key Metrics Changes - In Q1 2025, net product sales were $26 million, slightly ahead of expectations, compared to $31.9 million in the prior year quarter [5][13] - Adjusted EBITDA for Q1 was $200,000, down from $7.4 million in the prior year quarter, primarily due to lower net sales and gross margin [16] - GAAP net income for Q1 was a loss of $13.5 million, compared to a loss of $4.5 million in the prior year [16] Business Line Data and Key Metrics Changes - ROLVOIDON sales were $13.1 million, down from $14.5 million in the prior year, impacted by lower pricing but partially offset by higher volume [13] - SYMPAZAN sales decreased to $2.2 million from $2.6 million, affected by pricing and volume [14] - Indocin net product sales were $5.5 million, down from $8.7 million, due to generic competition [13] Market Data and Key Metrics Changes - The demand for ROLVOIDON remains strong, with expectations for net sales to continue increasing throughout the year [6] - The promotional strategy for SYMPAZAN has shown effectiveness, with total prescriptions up 6.5% year over year [6] Company Strategy and Development Direction - The company is in the transformation phase of its three-phase strategy, focusing on reducing legal exposure, simplifying corporate structure, prioritizing growth investments, divesting non-core assets, and leveraging its balance sheet for strategic transactions [8][9] - The growth phase is expected to begin in 2026, aiming to establish the company as a leading specialty pharma entity [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustainable near-term growth and increasing long-term value, despite challenges from generic competition and pricing pressures [18] - The company is optimistic about ongoing conversations for strategic transactions that could enhance its business [44] Other Important Information - The company has settled multiple legal matters, including significant lawsuits, which is expected to reduce legal costs and refocus resources on business operations [9][10] - As of March 31, 2025, cash and investments totaled $87.3 million, down from $100.1 million at the end of 2024 [16] Q&A Session Summary Question: Was there any value movement regarding the opioid litigation matters? - The company received nominal value in the settlement [20] Question: How should cash be used to bring down accrued liabilities? - The company expects to manage this relatively evenly throughout the year, primarily driven by ROLVOIDON's ASP-based pricing [21] Question: Any updates on same-day dosing progress with NCCN? - The company is on track for a publication in a peer-reviewed journal and plans to approach NCCN for inclusion in guidelines for 2026 [23][24] Question: Progress on expanding ROLVOIDON into the hospital setting? - The company is focusing on building payer coverage to unlock commercial channels and penetrate hospitals [29] Question: Why maintain the adjusted EBITDA guidance despite Q1 results? - The company believes there are still too many variables to adjust the guidance down at this time [30] Question: Expectations for Indocin's generic competition? - The company anticipates two more generics entering the market this year, which will impact revenue [39] Question: Any updates on strategic business development opportunities? - The company is optimistic about ongoing positive conversations for potential strategic transactions in 2025 [44] Question: Impact of tariffs and drug pricing changes? - The company does not foresee immediate risks from tariffs or drug pricing changes, as it primarily sells within the U.S. [57][59] Question: Confirmation of revenue guidance post-divestiture? - The company confirmed it is maintaining its revenue guidance of $108 million to $122 million [61]